key: cord-0921814-6e4vpr6s
authors: Umthong, Supawadee; Lynch, Brian; Timilsina, Uddhav; Waxman, Brandon; Ivey, Emily B.; Stavrou, Spyridon
title: Elucidating the antiviral mechanism of different MARCH factors
date: 2020-12-23
journal: bioRxiv
DOI: 10.1101/2020.12.22.422953
sha: 9aa74382a26731cfdc9958fc177787be908f3fa0
doc_id: 921814
cord_uid: 6e4vpr6s

The Membrane Associated RING-CH (MARCH) proteins belong to a family of E3 ubiquitin ligases, whose main function is to remove transmembrane proteins from the plasma membrane. Recent work has shown that the human MARCH1, 2 and 8 are antiretroviral factors that target the Human Immunodeficiency virus-1 (HIV-1) envelope glycoproteins by reducing their incorporation in the budding virions. Nevertheless, the dearth of information regarding the antiviral mechanism of this family of proteins necessitates further examination. In this study, using both the human MARCH proteins and their mouse homologues, we provide a comprehensive analysis of the antiretroviral mechanism of this family of proteins. Moreover, we show that human MARCH proteins restrict to varying degrees the envelope glycoproteins of a diverse number of viruses. This report sheds light on the important antiviral function of MARCH proteins and their significance in cell intrinsic immunity.

collected RNA and performed RT-PCR to determine their expression levels. We found that MLV 109 infection had no effect on mouse MARCH1, 2, 3 and 8 expression in all cell lines tested (Fig. 1E, 110 F and S1C). Thus, we concluded that MLV infection has no effect on mouse MARCH1, 2, 3 and 111 8 transcript levels and only mouse MARCH1 is an IFN stimulated gene. intracellularly but target them for degradation 115 To determine the effect mouse MARCH genes have on retrovirus envelope glycoproteins, we co-116 transfected 293T cells with an MLV molecular clone and with either an empty vector (E.V.) or 117 mouse MARCH1, 2, 3 or 8. Cells and the media were harvested 48 hours post-transfection 118 followed by western blots to determine the levels of the MLV envelope glycoproteins (gp70/SU 119 and p15E/p12E/TM). In the cell fractions, we found that the protein levels of both gp70 and 120 p15E were reduced in the presence of mouse MARCH1 and mouse MARCH8, while mouse 121 MARCH2 and 3 had no effect ( Fig. 2A) . Furthermore, virions produced in the presence of 122 mouse MARCH1 or 8 had significantly lower levels of gp70 and p12E than virions produced in 123 cells transfected with either E.V., mouse MARCH2 or 3 ( Fig. 2A) . By using varying levels of 124 mouse MARCH1 and mouse MARCH8, we found that mouse MARCH1 and 8 degraded gp70 125 and p15E in a dose dependent manner (Fig. 2B) . Interestingly, when probing for p15E in the cell 126 fractions, we observed a band (shown with an asterisk) migrating slightly faster than p15E when 127 using higher amounts of either mouse MARCH1 or mouse MARCH8, which probably reflects a In contrast to previous studies, our aforementioned data show that the cellular levels of the MLV 154 envelope glycoproteins (gp70 and p15E) are reduced in the presence of mouse MARCH1 and 8, 155 suggesting that the viral envelope glycoproteins are degraded and not sequestered intracellularly. 156 We hypothesized that the reason for this discrepancy is due to the difference in the species of 157 origin for the MARCH proteins we used in our system (mouse) vs. in previous reports (human). 158 To investigate this, we co-transfected 293T cells with an MLV molecular clone and with either 159 the human or mouse MARCH1, 2, 8 or an E.V. We observed that both human and mouse 160 MARCH1 and 8 abrogated the cellular levels of gp70 and p15E (Fig. 3A) . Interestingly, human 161 MARCH2, unlike mouse MARCH2, significantly reduced the cellular gp70 and p15E levels ( Fig   162   3A ). We thus concluded that mouse and human MARCH1 and 8 as well as human MARCH2 163 degrade and do not sequester intracellularly the MLV envelope glycoproteins. 164 We then speculated that HIV-1 envelope glycoprotein intracellular sequestration by the 165 human MARCH proteins might be virus-specific. Therefore, we examined the effect of human 166 and mouse MARCH1, 2 and 8 on HIV-1. 293T cells were co-transfected with NL4-3 (an HIV-1 167 lab strain) and either human or mouse MARCH1, 2 and 8 or an E.V. We found that all human 168 MARCH proteins (MARCH1, 2 and 8) decreased the cellular levels of both HIV-1 envelope 169 glycoproteins, gp120 and gp41 (Fig. 3B ). On the other hand, only mouse MARCH8 markedly 170 decreased the gp120 and gp41 cellular levels (Fig. 3B) . Mouse MARCH2, similar to what we 171 observed with MLV, had no effect (Fig. 3B (15, 19, 20, 22) , two tyrosine (Y) motifs (YXXΦ) 186 present in the C' terminal cytoplasmic tail (15, 21) and two TM domains (14) ( Fig. 4A and B ).

To determine the importance of these domains on retrovirus restriction, we generated a series of 188 mouse MARCH1 and MARCH8 constructs with mutations or deletions in the various domains. 189 We first verified that the mutant mouse MARCH1 and MARCH8 constructs continued to 190 localize in cellular membranes. In the case of mouse MARCH1, we transfected 293T cells with 191 the wild type and mutant MARCH1 constructs and then stained the cell surface of the transfected 192 cells with an anti-MARCH1 antibody followed by flow cytometry and found that all mouse 193 MARCH1 constructs localize on the plasma membrane (Fig. S2A) Previous studies have shown that the cytoplasmic tails of the immune receptors targeted by 221 MARCH proteins (e.g. MHC II) are critical for their removal from the cell surface (6, 15, 19, 26, 222 37). The MLV p15E contains a C' terminal cytosolic tail that is 35 amino acids long (38). To 223 determine if the cytoplasmic tail of p15E is critical for its MARCH-mediated removal from the 224 PM, we created an MLV molecular clone that did not express the cytoplasmic tail of p15E 225 (pMLVΔCT) by introducing a stop codon at the N' terminus of the p15E cytoplasmic tail region. 226 We co-transfected cells with an MLV infectious clone expressing either an intact p15E 227 cytoplasmic tail (pMLV) or pMLVΔCT in the presence of either mouse MARCH1, mouse 228 MARCH8 or E.V. We found that p15E with an intact cytoplasmic tail was degraded in the 229 presence of either mouse MARCH1 or 8, while p15E lacking the cytoplasmic tail was resistant to 230 the deleterious effect of mouse MARCH1 and 8 (Fig. 5A ). Paradoxically, we repeatedly noticed 231 that p15E lacking the cytoplasmic tail was detected in western blots at higher levels in the 232 presence of either MARCH1 or MARCH8 when compared to E.V. (Fig. 5A ), the reason for 233 which is unclear.

The retroviral envelope glycoprotein cytoplasmic tail ranges in size, with the cytoplasmic 235 tail of lentiviruses being the longest (27). Due to the differences in size and composition between 236 the MLV p15E and HIV-1 gp41 cytoplasmic tails, it is possible that unlike the MLV p15E 237 cytoplasmic tail, the HIV-1 gp41 cytoplasmic tail is dispensable for MARCH-mediated 238 restriction. Therefore, we generated an HIV-1 molecular clone that does not express the 239 cytoplasmic tail of gp41 (NL4-3ΔCT) by introducing two stop codons at the N' terminus of the 240 gp41 cytoplasmic tail. We co-transfected 293T cells with either NL4-3 with intact gp41 241 cytoplasmic tail (HIV-1) or NL4-3ΔCT (HIV-1ΔCT) and either human MARCH1, 2, 8 or E.V.

Unlike our findings with MLV, we noticed that the gp41 cytoplasmic tail is dispensable for 243 MARCH-mediated restriction (Fig. 5B ). In conclusion, the difference in the importance of the 244 cytoplasmic tail between gp41 and p15E for MARCH-mediated restriction suggests that 245 MARCH proteins may use different mechanisms to restrict MLV and HIV-1. with the mouse MARCH4 TM domains mentioned above (see Figure 4F ). MARCH4 does not 266 bind to p15E (Fig. S4C ). We found that changing the C' terminal TM domain (TM2) of mouse 267 MARCH8 to that of mouse MARCH4 abolished the mouse MARCH8-p15E interaction (Fig. 268 6D). In summary, our findings show that mouse MARCH1 and mouse MARCH8 physically 269 interact with the MLV p15E and while for mouse MARCH1, its interaction with p15E is TM-270 independent, mouse MARCH8 interacts with p15E via the C' terminal TM domain (TM2). 

While we observed a fairly broad antiviral effect by human MARCH1, 2 and 8 against a 326 variety of viral envelope glycoproteins, we also identified a number of viral envelope 327 glycoproteins that were resistant to human MARCH1, 2 and 8-mediated degradation. In the case 328 of two members of the paramyxovirus family we studied, we found that both Human 

MARCH proteins are membrane associated E3 ubiquitin ligases, whose main function is 358 to tightly regulate the levels of immune receptors by targeting them for degradation (e.g. MHC 359 II, Transferrin receptor, CD86 etc.) on the PM (1, 4, 9, 19, 51, 52) . Human MARCH1, 2 and 8 360 also target the HIV-1 envelope glycoproteins at the PM leading to their intracellular 361 sequestration blocking their incorporation in nascent virions (30-32). Nevertheless, many 362 questions remain regarding the antiviral mechanism of these host factors. MARCH8 is critical for restriction and interaction with MLV p15E. Our data thus suggest that 398 mouse MARCH1 and 8 may utilize different mechanisms to restrict MLV p15E. 399 We also show that the cytoplasmic tail of the MLV p15E, unlike that of HIV-1, is critical 400 for MARCH-mediated removal from the PM, similar to cellular immune receptors targeted by 401 MARCH proteins (6, 18, 19, 25, 53) . The variability in the importance of the retroviral 402 cytoplasmic tail on MARCH-mediated restriction further suggests that MARCH proteins may 403 utilize distinct mechanisms to restrict envelope glycoproteins from different retroviruses. 404 We also examined the role of MARCH1, 2 and 8 on the viral envelope glycoproteins 405 from a diverse number of enveloped viruses. We found that all three target the viral envelope Mutagenesis kit (Thermo Fisher Scientific). To generate the RING-CH mut mM1 and mM8, 493 mutations were introduced at C80S, C83S, C97S and C99S using the primers described in Table   494 I. To generate mM1 and mM8 ΔDIRT, we deleted residues 130 to 140 using the primers 495 described in Table I . To mutate the tyrosine endocytic motifs (YXXΦ) of mM1 ( 218 YVQL 221 and 496 228 YNRL 231 ) and mM8 ( 218 YLQL 221 and 228 YNRL 231 ), we mutated them to 218 AAQL 221 and 497 228 AARL 231 for both mM1 and mM8 using the primers shown in Table I . The 234 VQNC 237 motifs 498 of mM1 and mM8 were mutated to 234 AANC 237 using the primers mentioned in Table I . To 499 generate mM1 and mM8 carrying the TM domains of mM3 and mM4 respectively, we initially 500 PCR amplified the TM domains of mM3 and mM4 with the primers shown in Table I . We then 501 PCR amplified mM1 and mM8 with primers flanking their TM domains and described in Table   502 I. PCR products recombined using the NEBuilder HiFi DNA assembly kit (New England 503 Biolabs). All constructs were verified by sequencing. Table II followed by restriction digestion with BamHI   507 and XbaI and ligation into pcDNA-V5/His (Invitrogen). The MV H and HPIV-1 HN were PCR 508 amplified using the primers shown in Table II from Table II Resources, NIAID, NIH, NR-52285) using the primers in Table II and cloned into pCDNA-517 V5/His TOPO (Invitrogen). We introduced a FLAG tag to JUNV GP by PCR amplifying it from 518 a previously described expression plasmid (58, 59) using the primers in Table II and after   519 digestion with BamHI and XhoI was cloned into pCDNA TM 3.1/myc-His A (Invitrogen). CHIKV 520 structural genes were initially PCR amplified from pDONR21-CHKVstr (60) kindly provided to 521 us by Ted Pierson, using the primers shown in Table II Fisher Scientific) according to the manufacturer's recommendation. 293T cells were seeded on a 532 6-well plate (0.5 × 10 6 cells/well) and the following day were co-transfected with 3 μg of MLV 533 (pLRB3020) or 3 μg of pNL4.3 along with either 4 μg of pBJ5-mMARCHs (mM1, mM2, mM3, 534 or mM8) or with 4 μg of pBJ5-hMARCHs (hM1, hM2, or hM8). To study the dose-dependent 535 effect of mM1 and mM8, we used the following concentrations of mM1 and mM8: 0.25, 0.5, 1, To verify that the MARCH1 mutants we generated localized to the plasma membrane, we 595 seeded 0.5x10 6 293T cells and the following day, cells were transfected with 3 μg of E.V., mM1, BMDCs were transfected with the indicated siRNAs as described above and RNA was isolated 631 using the RNEasy mini kit (Qiagen). cDNA was generated using SuperScript III first-strand Fig 1. Expression levels of mMARCH1, 2, 3, and 8 

Primer sequence mM1-RING1-F 5'-/5Phos/ CAGGACATCTCCAGGATCTCTCACTGCGAA -3' mM1-RING1-R 5'-/5Phos/ AGTAGATGGACAGACAGACAACCTTGACT -3' mM1-RING2-F 5'-/5Phos/ ATCACACCCTCTCGCTCCACAGGAA -3' mM1-RING2-R 5'-/5Phos/ GAGTGGGCTCTCTTCATCTCCTTCGCA -3' mM8-RING1-F 5'-/5Phos/ CCAGGACATCTCCAGGATCTCCCACTG -3' mM8-RING1-R 5'-/5Phos/ TTGGATGGTGTGACAGAAGTGCGAG -3' mM8-RING2-F 5'-/5Phos/ CACCCCCTCTCACTCCACAGGGAGC -3' mM8-RING2-R 5'-/5Phos/ ATCAGAGGGCTCTCGTCATCCCCT -3' mM1-DIRT-F 5'-/5Phos/ CTCCAGATGACCACGAGC -3' mM1-DIRT-R 5'-/5Phos/ CTCCATTATGAAGTCATACTTGCA -3' mM8-DIRT-F 5'-/5Phos/ TTGCAGATGACTGCCAGT -3' mM8-DIRT-R 5'-/5Phos/ CTCCATGATGAACTCGTACTTG -3' mM1-YA1-F 5'-/5Phos/ GCCCAACTGTGGCGCC -3' mM1-YA1-R 5'-/5Phos/ GGCGACTTTACACTGTACATACAT -3' mM1-YA2-F 5'-/5Phos/ CTGAAGGCCGCCGCCCGTGT -3' mM1-YA2-R 5'-/5Phos/ CCGGCGCCACAGTTGGACGTAGACTTTAC -3' mM8-YA1-F 5'-/5Phos/ GCACAGTTATGGAAAAGACTCA -3' mM8-YA1-R 5'-/5Phos/ GGCCACCTTGCACTGAACA -3' mM8-YA2-F 5'-/5Phos/ GCTAGAGTGATCTATGTTCAGA -3' mM8-YA2-R 5'-/5Phos/ GGCAGCCTTGAGTCTTTTCC -3' mM1-VQNC-F 5'-/5Phos/ TGTGATCTTTGCGGCGAATTGCCCA -3' mM1-VQNC-R 5'-/5Phos/ CGGTTGTAGGCCTTCAGCCGG -3' mM8-VQNC-F 5'-/5Phos/ GTGATCTATGCTGCGAACTGTCCA -3' mM8-VQNC-R 5'-/5Phos/ TCTATTGTAAGCCTTGAGTCTTTTCC -3' mM3TM1-mM1- 

The Membrane Associated RING-CH Proteins: A Family of E3 728 Ligases with Diverse Roles through the Cell

Ubiquitin ligase MARCH 8 730 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell 731 selection

MARCH1-mediated MHCII ubiquitination 733 promotes dendritic cell selection of natural regulatory T cells

Inhibition of MHC 735 class II expression and immune responses by c-MIR

Ubiquitination regulates 737 MHC class II-peptide complex retention and degradation in dendritic cells

MHC class II 740 stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I 741 down-regulation

MARCH1 down-regulation in IL-10-743 activated B cells increases MHC class II expression

MARCH ubiquitin 745 ligases alter the itinerary of clathrin-independent cargo from recycling to degradation

Downregulation of major 748 histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins

Ubiquitylation of CD98 limits cell 751 proliferation and clonal expansion

DLG1 is an anchor for the E3 ligase 753 MARCH2 at sites of cell-cell contact

Overview of the membrane-associated RING-CH (MARCH) E3 755 ligase family

The trafficking and regulation of membrane receptors by the RING-CH 757 ubiquitin E3 ligases

Autoregulation of MARCH1 expression by dimerization 759 and autoubiquitination

Identification of a novel motif that affects the 761 conformation and activity of the MARCH1 E3 ubiquitin ligase

The position of the Gly-xxx-Gly motif in transmembrane 763 segments modulates dimer affinity

Self-clearance mechanism of mitochondrial E3 ligase 765 MARCH5 contributes to mitochondria quality control

The specificities of Kaposi's sarcoma-associated herpesvirus-encoded E3 767 ubiquitin ligases are determined by the positions of lysine or cysteine residues within the intracytoplasmic 768 domains of their targets

Ubiquitin-770 mediated regulation of CD86 protein expression by the ubiquitin ligase membrane-associated RING-CH-771 1 (MARCH1)

Discrete domains of MARCH1 mediate its 776 localization, functional interactions, and posttranscriptional control of expression

Downregulation of cell surface receptors by the K3 779 family of viral and cellular ubiquitin E3 ligases

Structural requirements for recognition of major 781 histocompatibility complex class II by membrane-associated RING-CH (MARCH) protein E3 ligases

The E3 ubiquitin ligase MARCH8 negatively 784 regulates IL-1beta-induced NF-kappaB activation by targeting the IL1RAP coreceptor for ubiquitination 785 and degradation

Ubiquitination of human leukocyte antigen (HLA)-DM by 787 different membrane-associated RING-CH (MARCH) protein family E3 ligases targets different endocytic 788 pathways

R-Peptide cleavage potentiates fusion-795 controlling isomerization of the intersubunit disulfide in Moloney murine leukemia virus Env

pH-independent murine leukemia virus ecotropic envelope-mediated 798 cell fusion: implications for the role of the R peptide and p12E TM in viral entry

MARCH8 801 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins

MARCH2 is upregulated in HIV-1 infection and inhibits HIV-1 production 804 through envelope protein translocation or degradation

Membrane-associated RING-806 CH (MARCH) 1 and 2 are MARCH family members that inhibit HIV-1 infection

Novel murine 808 dendritic cell lines: a powerful auxiliary tool for dendritic cell research

Construction of a clonable, infectious, and tumorigenic mouse 810 mammary tumor virus provirus and a derivative genetic vector

Myristylation is required for intracellular transport but not for assembly of D-813 type retrovirus capsids

Basic residues in the matrix domain and multimerization 815 target murine leukemia virus Gag to the virological synapse

Ubiquitination of HLA-DO by MARCH family E3 ligases

Two distinct mechanisms regulate recruitment 819 of murine leukemia virus envelope protein to retroviral assembly sites

MARCH1-mediated 821 ubiquitination of MHC II impacts the MHC I antigen presentation pathway

Endoproteolytic processing of the 824 lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P

Mechanisms for lymphocytic 827 choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions

Novel innate immune 830 functions for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope glycoproteins and 831 augments dendritic cell secretion of proinflammatory cytokines

A Novel Coronavirus from Patients with 835 Pneumonia in China

Characterization of spike glycoprotein of SARS-837

CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Coronavirus envelope protein: current knowledge

Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics?

The M protein of SARS-CoV: basic 844 structural and immunological properties

The M, E, and N structural proteins 846 of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and 847 release of virus-like particles

Differential maturation and subcellular 849 localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E

Ubiquitination of CD86 is a key mechanism in regulating antigen presentation by dendritic cells

E3 ubiquitin ligases for MHC molecules

The HLA-DRalpha chain is modified by 857 polyubiquitination

Studies on 859 membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein

Different modes of 862 retrovirus restriction by human APOBEC3A and APOBEC3G in vivo

Hemolytic anemia and 865 erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different 866 regions of the viral genome

Production of acquired 868 immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an 869 infectious molecular clone

Transferrin 871 receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses

Site-specific antibodies 874 define a cleavage site conserved among arenavirus GP-C glycoproteins

Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: 879 identification of receptor-deficient cell lines

Arenavirus Z-glycoprotein 881 association requires Z myristoylation but not functional RING or late domains

Receptor use 884 by pathogenic arenaviruses

Nipah virus envelope-886 pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the 887 liver sink when administered in vivo

A novel approach for the 889 rapid mutagenesis and directed evolution of the structural genes of west nile virus

The hypervariable domain of the murine leukemia virus 892 surface protein tolerates large insertions and deletions, enabling development of a retroviral particle 893 display system

Cells were incubated with either (A) 100 μM 1000 chloroquine or (B) 16 μM MG132. Cells were harvested 24 hours post transfection and lysates 1001 were analyzed by immunoblotting using anti-MLV p30 (detects p65 Gag ), anti-MLV p15E, anti-1002 myc (for mM1 and 8 detection) and anti-β-actin antibodies. Results are shown for n=3 1003 independent experiments

Fig 8. Endogenous mouse MARCH1 and mouse MARCH8 restrict MLV infection

Cells were harvested 6 and 24 hours post infection and MLV 1009 DNA levels were examined by RT-qPCR. (C-D) Knockdown verification of mouse MARCH1 1010 (mM1) and mM8 from siRNA transfected BMDCs relative to siControl (siCtl) in (A) and (B) by 1011 either (C) RT-PCR or (D) immunoblotting. Data shown represent averages of results from n=5 1012 independent experiments. Results for (A) through (C) are presented as means ± standard error of 1013 the mean (SEM)

MARCH proteins target envelope glycoproteins from a diverse number of viral 1019 families. (A) Ebola virus (EBOV) mature envelope glycoprotein Gp2

(D) Influenza A 1022 Virus (IAV) hemagglutinin (HA), (E) Zikka virus (ZIKV) E and (F) Chikungunya virus 1023 (CHIKV) E1 and E2 protein levels in the presence of human MARCH1 (hM1), MARCH2 1024 (hM2), MARCH8 (hM8) and empty vector (E.V). 293T cells were co-transfected with either (A) 1025 EBOV glycoprotein (Gp), (B) LCMV Gp, (C) NiV F or NiVG

At 24 hours post transfection, cells were lysed and analyzed by western blots using anti-V5 1028 (for EBOV GP2 and IAV HA detection), anti-FLAG (for LCMV GP2 detection)

MARCH8 (hM8) 1038 and empty vector (E.V.). 293T cells were co-transfected with SARS-CoV-2 S (A) or M (B) and 1039 either hM1, 2, 8 or E.V. At 24 hours post transfection, cells were lysed and analyzed by western 1040 blots using anti-SARS-CoV-2 S

The *, # and Δ symbols represent 1042 different glycosylated forms of SARS-CoV-2 M. Shown are the results of a single experiment 1043

Fold expression changes of mouse MARCH1, 2, 3 and 8 1048 (mM1, 2, 3 and 8) relative to untreated cells and normalized to GAPDH in (A) EL4 mouse T cell 1049 line and (B) NIH3T3 mouse fibroblasts treated with 500 Units/mL of mouse IFN-β and harvested 1050 at 0, 4, 8, 16 and 24 hours post treatment. (C) Fold expression changes of mM1, 2, 3, and 8 relative 1051 to uninfected cells and normalized to GAPDH in (E) NIH3T3 cells at 4, 8, 16 and 24 hours post 1052 infection with MLV (5 MOI). (D) Purity of bone marrow derived macrophages (BMDMs) and 1053 (E) bone marrow derived dendritic cells (BMDCs) used in Fig 1 was confirmed by staining with 1054 either (D) the macrophage cell surface antibody CD11b-FITC or (E) the dendritic cell surface 1055 antibody CD11c-APC. Data shown represent averages of results from n=3 independent 1056 experiments. All results are presented as means ± standard error of the mean (SEM)

Mouse MARCH1 and mouse MARCH8 localize in cellular membranes. (A) Wild 1061 type (WT) mouse MARCH1 (mM1) and mM1 mutants (RING mut , ΔDIRT, TM1 mM3 , TM2 mM3

293T cells were transfected with mM1 constructs used in Fig 4 and 6. Cells were 1064 harvested and surface stained with anti-MARCH1 or rabbit IgG isotype control followed by anti-1065 rabbit IgG (Alexa Fluor 647) and analyzed by flow cytometry. Histogram plots indicate percent of 1066 cells expressing mM1 on the cell membrane. (B) and (C) Wild type (WT) mouse MARCH8 (mM8) 1067 and mM8 mutants (RING mut , ΔDIRT, TM1 mM4 , TM2 mM4 , TM1/2 mM4 , 218 AAQL 221 , 228 AARV 231 1068 and VQNC mut ) localize in the cellular membranes of the transfected cells. 293T cells were 1069 transfected with the various mM8 constructs used in Figure 4 and 6. Cells were harvested and 1070 integral membrane proteins were extracted using the MEM-PER plus membrane extraction kit 1071

For empty vector (E.V) and mM8 WT transfection we provide the membrane fraction (M) and cellular fraction (C). Shown are the results 1074 of a single experiment

The VQNC motif does not affect mouse MARC1-and mouse MARCH8-1078 mediated degradation of the retroviral envelope glycoprotein restriction. 293T cells were 1079 co-transfected with an MLV infectious clone and either with mouse MARCH1 (mM1), mM8, 1080 mM1 with mutations in the VQNC domain (VQNC mut ) or mM8 VQNC mut . Cells were harvested 1081 48 hours post transfection and lysates were analyzed by immunoblotting using anti-MLV p30 1082 (detects p65 Gag ), anti-MLV gp70, anti-MLV p15E, anti-myc (for detection of mM1 and 8) and 1083 anti-β-actin antibodies

At 1090 48 hours post transfection, cells and released virus in the culture media were harvested and the 1091 indicated proteins were analyzed by immunoblotting using anti-MLV p30 (detects p30 and 1092 p65 Gag ), anti-MLV gp70, anti-MLV p15E/p12E, anti-myc (for detection of mM4) and anti-β-1093 actin antibodies. Shown are the results of a single experiment (representative of three 1094 independent experiments). (B) Mouse MARCH3 does not interact with MLV p15E. 293T cells were co-transfected with an MLV infectious clone and either (B) mM1 or mM3 and were 1096 harvested 48 hours post transfection. Cell lysates were immunoprecipitated with anti-myc (mM1 1097 and mM3) followed by western blots probing with anti-myc (mM3) or anti-15E

Viral envelope glycoproteins vary in their susceptibility to MARCH-mediated 1102 restriction. (A) Lassa virus (LASV) mature envelope glycoprotein GP2, (B) Junín virus (JUNV) 1103 mature envelope glycoprotein GP2 (arrow)

(E) West Nile 1105 virus (WNV) envelope (E) and Crimean Congo hemorrhagic fever virus (CCHFV) mature 1106 envelope glycoprotein Gc protein levels in the presence of human MARCH1 (hM1), hM2, hM8 1107 and empty vector (E.V.). 293T cells were co

M segment along with either hM1, 2 1109 8 or E.V. Cells were harvested 24 hours post transfection, lysed and analyzed by western blots 1110 using anti-V5 (for HPIV-1 HN and MV H detection), anti-FLAG (for LASV GP2 and JUNV GP2 1111 detection), anti-Flavivirus E antibody (clone 4G2 for WNV E detection

Shown are the results of a single 1113 experiment (representative of three independent experiments)

CCGP3-R 5'-TGCAGAATTGCCCTTGCCAATGTGTGTTTTTGTAG -3' pcDNA-CC-F 5'-AAAACACACATTGGCAAGGGCAATTCTGCAGATATCC -3' pcDNA-CC-R 5

 718 We thank Leonard "Pug" Evans, Susan Ross, Christine Kozak, Hans Orbea-Acha, Xinqi Liu,

Benhur Lee, Amy Jacobs, Paul Bates and Ted Pierson for kindly providing us with reagents used 720 for this project. We also thank Michael Battaglia and Sydney Herring for technical support with